FY2020 Management Target Figures
First written in FY2018. 2 of 7 entries say "Raised", first in FY2019. Latest entry: FY2026.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2026RestatedAnnual report
「The Company has established the following management targets for FY2027, the final year of the 25-27 Medium-Term Management Plan. These targets have been set from the perspective of comprehensively evaluating investment for future growth in addition to sales scale and profit levels.」
The existing management targets of FY2027 net sales of ¥120.0 billion, operating profit of ¥12.0 billion and EBITDA + R&D expenses of ¥26.5 billion are being restated. - FY2025RaisedAnnual report
「The Company has established the following management targets for FY2027, the final year of the 25-27 Medium-Term Management Plan. FY2027 management targets (consolidated): net sales ¥120.0 billion; operating profit ¥12.0 billion; EBITDA + R&D expenses ¥26.5 billion.」
The targets have been updated from the FY2024 targets under the previous 22-24 Medium-Term Management Plan to FY2027 targets of net sales of ¥120.0 billion, operating profit of ¥12.0 billion and EBITDA + R&D expenses of ¥26.5 billion. The net sales and operating profit targets exceed the previous targets of ¥106.0 billion and ¥7.5 billion, respectively, and the metric has also been changed. - FY2024Restatement of numerical targetsAnnual report
「The Company has established the following management targets for FY2024, the final year of the 22-24 Medium-Term Management Plan. FY2024 management targets (consolidated): net sales ¥106.0 billion; operating profit ¥7.5 billion; R&D expenses ¥13.2 billion.」
After deciding not to formulate or disclose numerical targets under the 21-23 Medium-Term Management Plan, the Company has stated numerical targets for net sales, operating profit and R&D expenses for the final year of the 22-24 Medium-Term Management Plan. - FY2021DroppedAnnual report
「The Company has traditionally disclosed management targets for the final year of its medium-term management plan. However, because it is extremely difficult to predict the extent and speed of the impact on the industry environment from developments such as future revisions to the drug pricing system, it has decided not to formulate or disclose management targets for the final year of the 21-23 Medium-Term Management Plan.」
For the 21-23 Medium-Term Management Plan, the Company has decided not to formulate or disclose the previously established numerical targets for net sales, operating profit and R&D expenses in the final year of the plan. - FY2020ReframedAnnual report
「The Company has established the following management targets for FY2022, the final year of the 20-22 Medium-Term Management Plan. FY2022 management targets (consolidated): net sales ¥104.0 billion; operating profit ¥10.0 billion; R&D expenses ¥13.0 billion.」
The targets have been updated from the FY2021 targets under the 19-21 Medium-Term Management Plan to the FY2022 targets under the 20-22 Medium-Term Management Plan. The targets for net sales and operating profit are below the previous targets, while the target for R&D expenses is higher. - FY2019RaisedAnnual report
「The Company has established the following management targets for FY2021, the final year of the 19-21 Medium-Term Management Plan. FY2021 management targets (consolidated): net sales ¥108.0 billion; operating profit ¥11.0 billion; R&D expenses ¥12.0 billion.」
The targets have been updated from the previous FY2020 targets to the FY2021 targets, and all of the targets for net sales, operating profit and R&D expenses exceed the previous targets. - FY2018First statedAnnual report
「The Company has established the following management targets for FY2020, the final year of the 18-20 Medium-Term Management Plan. FY2020 management targets (consolidated): net sales ¥103.0 billion; operating profit ¥8.5 billion; R&D expenses ¥10.0 billion.」
For FY2020, the final year of the 18-20 Medium-Term Management Plan, numerical targets for net sales, operating profit and R&D expenses have been disclosed for the first time.